Home » Stocks » AYTU

Aytu BioScience, Inc. (AYTU)

Stock Price: $6.44 USD -0.06 (-0.92%)
Updated Apr 20, 2021 4:00 PM EDT - Market closed
After-hours: $6.52 +0.08 (1.24%) Apr 20, 7:45 PM
Market Cap 151.61M
Revenue (ttm) 51.68M
Net Income (ttm) -22.31M
Shares Out 13.28M
EPS (ttm) -2.22
PE Ratio n/a
Forward PE 10.70
Dividend n/a
Dividend Yield n/a
Trading Day April 20
Last Price $6.44
Previous Close $6.50
Change ($) -0.06
Change (%) -0.92%
Day's Open 6.50
Day's Range 6.27 - 6.54
Day's Volume 382,160
52-Week Range 5.86 - 21.30

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indications Program initially targeting vascular Ehlers-Danlos Syndrome ...

1 week ago - Accesswire

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Interactive Brokers (IBKR), Avid (CDMO), Oncternal (ONCT), Amtech (ASYS) and Aytu.

Other stocks mentioned: ASYS, CDMO, IBKR, ONCT
1 week ago - Zacks Investment Research

ENGLEWOOD, CO / ACCESSWIRE / April 5, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today ...

2 weeks ago - Accesswire

Strategic Transaction Provides $7.5M in Non-Dilutive Capital and Enables Pediatric and ADHD Product Focus Following the Recently Closed Merger with Neos Therapeutics ENGLEWOOD, CO / ACCESSWIRE / April 1...

2 weeks ago - Accesswire

Reddit penny stocks continue to be of interest to risky investors and InvestorPlace is looking at the top ones for Monday. The post 10 Reddit Penny Stocks Seeing the Most Chatter Today appeared first on...

Other stocks mentioned: BNGO, CTXR, DNN, HOFV, IDEX, MRKR, NEOS ...
4 weeks ago - InvestorPlace

$100M revenue specialty pharmaceutical company on an accelerated path to profitability[1] Company name change to Aytu BioPharma, Inc. becomes effective today Former Neos Therapeutics board members Beth ...

4 weeks ago - Accesswire

Aytu Biosciences Inc. (NASDAQ: AYTU) shares gapped up Thursday morning. The price jump is speculatively from the meetings the company is having about the proposed merger with Neos Therapeutics Inc. (NAS...

1 month ago - Benzinga

NEOS stock holders will get AYTU stock in this no-cash merger transaction. Today's vote has the support of two proxy advisory firms.

1 month ago - InvestorPlace

Neos Therapeutics Inc (NASDAQ: NEOS) and Aytu BioScience Inc (NASDAQ: AYTU) shares are rising today in the premarket session, though there is no news on both companies. The investors are reacting to the...

Other stocks mentioned: NEOS
1 month ago - Benzinga

Aytu Bioscience, Inc. (AYTU) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near t...

1 month ago - Zacks Investment Research

Aytu BioScience Inc (NASDAQ: AYTU) rises sharply in the premarket after first-in-human data with endotracheal UVA light catheter therapy show positive outcome in SARS-CoV-2 patients.  Known as Healight,...

1 month ago - Benzinga

Data indicate endotracheal UVA light catheter therapy reduces SARS-CoV-2 viral load and improves clinical outcomes in mechanically ventilated SARS-CoV-2 patients  ENGLEWOOD, CO / ACCESSWIRE / March 8, 2...

1 month ago - Accesswire

Getting a big headache watching large-cap S&P 500 stocks lose steam? Small-cap stocks are giving investors a new way to make big money.

Other stocks mentioned: AGTC, ATOM, CODX, CRTX, DVAX, SRNE
1 month ago - Investors Business Daily

Bet on these top-ranked stocks with rising P/E to realize outsized gains.

Other stocks mentioned: CEO, GFI, GTY, LEN, QTS
2 months ago - Zacks Investment Research

Long-term investors in Aytu BioScience have endured a series of value and confidence eroding actions by the company over the last 12 months including dilution and reverse splits. Aytu has significant up...

3 months ago - Seeking Alpha

Osmotica Pharmaceuticals (NASDAQ: OSMT) shares were trading higher Monday in anticipation of a ruling by the FDA on the company's New Drug Application for Arbaclofen ER in patients with multiple scleros...

Other stocks mentioned: KNTE, MYOV, OSMT
3 months ago - Benzinga

First Safety Study Utilizing Ultraviolet A Light Catheter as a Prospective Anti-Infective in Critically Ill, Intubated SARS-Cov-2 Patients ENGLEWOOD, CO / ACCESSWIRE / December 28, 2020 / Aytu BioScienc...

3 months ago - Accesswire

NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Neos Therapeutics, Inc. (NASDAQ: NEOS) and its board of directors concerning the proposed ...

Other stocks mentioned: NEOS
4 months ago - PRNewsWire

The day dawned as an M&A Thursday for the biotech sector, as a slew of deals of varied sizes were announced, with Gilead Sciences, Inc. (NASDAQ: GILD) and Aytu BioScience, Inc. (NASDAQ: AYTU) in the mix...

Other stocks mentioned: GILD
4 months ago - Benzinga

Aytu reported Q4 results in October that beat estimates across the board with revenue of $14.86 million, surpassing the $11.24 million revenue analysts were projecting. A careful review of the data supp...

5 months ago - Seeking Alpha

Shares of Aytu BioScience (NASDAQ:AYTU) fell 6.77% after the company reported Q4 results. Quarterly Results Earnings per share rose 98.46% over the past year to ($0.02), which beat the estimate of ($0.03).

6 months ago - Benzinga

Aytu BioScience (NASDAQ: AYTU) releases its next round of earnings this Tuesday, October 06. Get the latest predictions in Benzinga's essential guide to the company's Q4 earnings report.

6 months ago - Benzinga

On Thursday, September 24, Aytu BioScience (NASDAQ: AYTU) will release its latest earnings report.

6 months ago - Benzinga

Aytu (AYTU) will provide financial updates when it reports fourth-quarter fiscal 2020 results.

8 months ago - Zacks Investment Research

Aytu Bioscience, Inc. (AYTU) closed at $1.39 in the latest trading session, marking a +1.46% move from the prior day.

8 months ago - Zacks Investment Research

Is (AYTU) Outperforming Other Medical Stocks This Year?

9 months ago - Zacks Investment Research

Some small companies are destined to be small forever. Others can grow into massive companies over time.

9 months ago - 24/7 Wall Street

Aytu Bioscience, Inc. (AYTU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

9 months ago - Zacks Investment Research

Aytu BioScience: The Next Arbor Pharmaceuticals?

10 months ago - Seeking Alpha

Aytu BioScience (AYTU) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

10 months ago - Zacks Investment Research

Aytu BioScience Inc. (NASDAQ: AYTU) stock has been a huge beneficiary of the coronavirus pandemic.

10 months ago - 24/7 Wall Street

Aytu BioScience, Inc. (NASDAQ: AYTU) has been one of the biggest winners from COVID-19.

10 months ago - 24/7 Wall Street

Is (AYTU) Outperforming Other Medical Stocks This Year?

10 months ago - Zacks Investment Research

Aytu BioScience, Inc. (NASDAQ: AYTU) is a specialty pharmaceutical company focused on commercializing novel products related to low testosterone, upper respiratory problems, insomnia, and more.

10 months ago - 24/7 Wall Street

Aytu BioScience, Inc.'s (AYTU) CEO Joshua Disbrow on Q3 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Aytu Bioscience, Inc. (AYTU) delivered earnings and revenue surprises of 61.54% and 16.51%, respectively, for the quarter ended March 2020.

11 months ago - Zacks Investment Research

Aytu BioScience Inc. (NASDAQ: AYTU) has been a stock market darling since it broke onto the COVID-19 testing scene.

11 months ago - 24/7 Wall Street

Aytu Bioscience Inc (AYTU) closed the most recent trading day at $1.47, moving +1.38% from the previous trading session.

11 months ago - Zacks Investment Research

Aytu Bioscience, Inc. (AYTU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

11 months ago - Zacks Investment Research

Aytu Bioscience, Inc. (AYTU) closed at $1.64 in the latest trading session, marking a +1.23% move from the prior day.

11 months ago - Zacks Investment Research

On March 9, pharmaceutical company Aytu Bioscience Inc. (NASDAQ: AYTU) posted a 52-week low of $0.34 per share.

11 months ago - 24/7 Wall Street

On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its distribution right to commercialize the COVID-19 IgG/IgM Rapid Test in North America.

11 months ago - Zacks Investment Research

Aytu BioScience Inc. (NASDAQ: AYTU) shares made an incredible gain to start the week following the firm’s announcement in regards to a coronavirus treatment.

11 months ago - 24/7 Wall Street

Aytu BioScience's (AYTU) CEO Josh Disbrow on COVID-19 Initiatives - Update Call

11 months ago - Seeking Alpha

Is (AYTU) Outperforming Other Medical Stocks This Year?

11 months ago - Zacks Investment Research

Aytu BioScience: A Corona-Portunist With 40%+ Downside

1 year ago - Seeking Alpha

Aytu BioScience Inc. (NASDAQ: AYTU) has been one of the biggest winners in the fight against the novel coronavirus.

1 year ago - 24/7 Wall Street

Aytu Bioscience, Inc. (AYTU) closed at $1.55 in the latest trading session, marking a -1.27% move from the prior day.

1 year ago - Zacks Investment Research

Aytu Bioscience, Inc. (AYTU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

1 year ago - Zacks Investment Research

Aytu Bioscience, Inc. (AYTU) closed at $1.52 in the latest trading session, marking a -1.3% move from the prior day.

1 year ago - Zacks Investment Research

About AYTU

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension. It also offers ZolpiMist, an oral spray f... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
AYTU
Full Company Profile

Financial Performance

In 2020, AYTU's revenue was $27.63 million, an increase of 277.47% compared to the previous year's $7.32 million. Losses were -$13.62 million, -49.80% less than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for AYTU stock is "Buy." The 12-month stock price forecast is 20.60, which is an increase of 219.88% from the latest price.

Price Target
$20.60
(219.88% upside)
Analyst Consensus: Buy